Clinical Trial Search

Primary: Number of Participants With Non Coronary Artery Bypass Graft-Related (Non CABG-related) Thrombolysis in Myocardial Infarction (TIMI) Clinically Significant Bleeding…

Primary: Number of Participants With Serum Creatinine Event of Grade 1 or Higher Over the Course of the Study — 0 Participants

Primary: Percentage of Participants Who Have a Physician Global Assessment (PGA) Score of 0 or 1 at Week 12 and a Minimum 2-grade Improvement in PGA Score From Baseline to Week…

Primary: Number of Participants With Adverse Events — 4 Participants

Primary: Percentage of Participants Achieving SVR12 (Sustained Virologic Response 12 Weeks After the End of All Study Therapy) — 91.3; 100.0; 100.0; 100.0 Percentage of…

Primary: Objective Response Rate — 8 percentage of patients

Primary: Change From Baseline in Newcastle Paediatric Mitochondrial Disease Scale (NPMDS) Sections I-IV — -0.3; 0.1; -0.6; 0.0 units on a scale — p=0.1875

Primary: Progression Free Survival — 4.53; 6.83 months — p=0.231

Primary: Relative Tumor Size Change Following 8 Weeks of Therapy. — 1.4; -0.57 Percent change from baseline — p=0.69

Primary: Number of Participants With Dose Limiting Toxicities — 0; 2; 2; 0 Participants

Primary: 7-month Progression-Free Survival — 0.581; 0.582 probability

Primary: Disease Progression — 1; 0 Participants

Primary: Modeled Hgb Change From Baseline Over 4 Weeks of Treatment — -0.148; 0.132; 0.463; 1.010 gram per decilitre (g/dL) — p=0.5888

Primary: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)- Part A — 0; 2; 0; 0 Participants

Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Day 85 — 4.05; -14.95; -44.84 percent change — p=0.0137